ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Cardiome To Slash Workforce by 85% on End of Merck's Oral Development Program

By Chelsea Stevenson Cardiome Pharma Corp. (CRME) plans to reduce its workforce by about 85% in response to the termination of Merck & Co.'s (MRK) developing vernakalant oral program. All positions focused on internal research and certain supporting functions will be eliminated, Canadian-based Cardiome Pharma said. The reductions will result in up to $5 million in severance charges over the remainder of the year. In March, Cardiome's partner Merck discontinued its development of its oral vernakalant drug, which prevented atrial fibrillation. Cardiome had said it was disappointed with Merck's decision. Interim Chief Executive Dr. William Hunter said the board regrets the effects of the decision. Dr. Hunter replaced former Chief Executive Doug Janzen, who left the company last week. Cardiome Pharma reported a slightly narrower loss for its first quarter, citing clinical development efforts and pre-clinical research project expenditures. The latest quarter's loss also includes employee termination charges. The company said it will issue a further progress report in mid-August to its shareholders. Shares were off 2.3% to 43 cents in recent trading and have dropped 84% this year. Write to Chelsea Stevenson at

Stock News for Merck (MRK)
12/01/201507:38:02The Path Is Clear for a New Immunotherapy Entrant
11/30/201508:30:00New Survey Showed That Most People Living With HIV Were More...
11/25/201508:00:07How Big Could This Drug Be for Opko Health?
11/24/201512:35:00Merck Announces Increased Quarterly Dividend
11/24/201507:41:03This Metric Implies That It Might Be Time to Buy Big Pharma Stocks
11/23/201510:01:03Can Merck & Co. Take Down Gilead Sciences?
11/22/201509:12:02Beyond Chemotherapy: 4 Unique Ways Drug Developers Are Fighting...
11/21/201516:30:00Merck Announces Initial Results for KEYTRUDA® (pembrolizumab...
11/21/201509:04:08Gilead Sciences Inc. Has Plenty of Room to Run in Hepatitis C
11/20/201517:55:00Celldex Vaccine Rindopepimut Cuts Death Risk From Brain Cancer...
11/20/201507:40:02Merck & Co.'s Cholesterol-Buster Program Isn't (Yet) an Exercise...
11/19/201506:30:00Lilly and Merck Expand Immuno-oncology Collaboration with Phase...
11/18/201510:18:035 Things Merck & Co., Inc. Wants You to Know
11/17/201515:52:03Why Novavax Inc Is Moving Higher Today
11/17/201510:59:02Here's Why Advaxis' Stock Gained 11% in October
11/17/201508:00:00New Studies Investigating the Use of KEYTRUDA® (pembrolizumab...
11/16/201509:19:033 High-Yield Dividend Stocks You Don't Have to Babysit
11/16/201508:30:00Merck Announces Presentation of Results from Two Phase 2 Studies...
11/15/201518:00:03Exelixis, Inc. Earnings: Riding the Meteor
11/14/201519:00:00Merck Announces Presentation of Phase 3 Results of Investigational...

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations